“Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s63, https://doi.org/10.25251/skin.5.supp.63.